Looking ahead, the future growth of affordable medicine in Germany will be significantly fueled by the patent expirations of major biologic drugs and the subsequent introduction of biosimilars. Biologics, which are high-cost, high-value therapies, represent a massive cost-saving opportunity once they face generic-like competition. Biosimilars—which are essentially the generic equivalent...